Skip to content

Trial · Interventional

CompletedNot applicableResults postedRegistry data

Effect of NMN Supplementation on Organ System Biology

Short name VAN

NCTNCT04571008 (opens ClinicalTrials.gov in a new tab)Other id201909118
Open at ClinicalTrials.govAsk about this trial

This trial does not test a peptide that PepBank tracks.

  • Names NMN (nicotinamide mononucleotide), does not test it. It appears in the title.

Overview

Status
Completed
Phase
Not applicable
Enrollment
56 participants (actual)
Sponsor
Washington University School of Medicine · Other
Design
Randomized · Quadruple masking
Countries
1 country

United States

Start
1 Oct 2020
Primary completion
4 Mar 2025
Completion
4 Mar 2025
First posted
30 Sept 2020
Last update posted
10 Sept 2026
Conditions
Glucose Metabolism Disorders

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2020202120222023202420252026
  1. N/A

    VAN

    NCT04571008

    1 Oct 2020 to 4 Mar 2025

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The goal of this proposal is to determine whether the beneficial effects of NMN on metabolic function observed in rodents applies to people.

Interventions

  • PlaceboOther
  • TreatmentDietary supplement

Arms2

  • Placebo comparator

    Placebo

    At least 16 weeks of placebo.

  • Experimental

    NMN supplementation

    At least 16 weeks of NMN.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Change in Muscle Insulin Sensitivity

    Time frame · After 16 weeks of treatment

    Registry description

    The outcome (mean change in muscle sensitivity from baseline to after intervention) will be assessed during hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopic tracer infusion after intervention period.

Secondary outcomes(1)

  1. Changes in Glucose Tolerance

    Time frame · After 16 weeks of treatment

    Registry description

    The outcome (mean change in oral glucose tolerance from baseline to after intervention) will be assessed during modified oral glucose tolerance test after the intervention

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeMean· After 16 weeks of treatment

Change in Muscle Insulin Sensitivity

GroupValue ((nmol/kg FFM/min) / (µU/mL))Spread
Placebo19.095.0
NMN Supplementation13.588.4
Secondary and other outcome results(1)
Secondary outcomeMean· After 16 weeks of treatment

Changes in Glucose Tolerance

GroupValue (mg/dLx3 Hr)Spread
Placebo-9.038.0
NMN Supplementation1442

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
PlaceboAt least 16 weeks of placebo.0 / 280 / 2811 / 28
NMN SupplementationAt least 16 weeks of NMN.0 / 280 / 2810 / 28

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 45 Years up to 75 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * BMI 25.0-50.0 kg/m² * Prediabetes defined as fasting plasma glucose of ≥100 mg/dL, or HbA1C ≥5.7, or HOMA-IR ≥2.5. Exclusion Criteria: * Women who are still having menses * Persons who take niacin, nicotinamide, or other vitamin B3-related supplementation and are not willing to discontinue supplementation for 3 weeks before medical screening and during the entire study period * Persons who consume moderate-large amounts of caffeine daily (\>2 cups of coffee or 8 oz caffeinated drinks per day) or consume less amounts of caffeine but believe withdrawal symptoms (e.g. headache) are likely if caffeine is stopped * Unstable weight (\>3% change during the last 2 months before entering the study)

PepBank is a research reference. Talk to a doctor before you use any peptide.